<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846634</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-L043</org_study_id>
    <nct_id>NCT04846634</nct_id>
  </id_info>
  <brief_title>Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)</brief_title>
  <acronym>ALTER-L043</acronym>
  <official_title>Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label, phase II study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open label, phase II study assessing the efficacy and&#xD;
      safety of penpulimab plus chemotherapy or penpulimab plus anlotinib or penpulimab plus&#xD;
      chemotherapy and anlotinib as neoadjuvant/adjuvant treatment in patients with resectable&#xD;
      locally advanced non-small cell lung cancer. Eligible patients will be randomized to receive&#xD;
      either penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) or&#xD;
      penpulimab (200mg, iv, Q3W) plus anlotinib (12mg, po, day 1-14, Q3W) or penpulimab (200mg,&#xD;
      iv, Q3W) plus chemotherapy (platinum based chemotherapy) and anlotinib (12mg, po, day 1-14,&#xD;
      Q3W) in a 1:1:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response (MPR)</measure>
    <time_frame>About 3-6 weeks following completion of surgery.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Within 7 days before surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year Event-Free Survival rate</measure>
    <time_frame>Up to 5 Years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Up to 5 years from randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years from randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)/serious adverse events (SAEs)</measure>
    <time_frame>Up to 5 Years from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Resectable Locally Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel</intervention_name>
    <description>A cycle of treatment is defined as 21 days of once daily treatment.</description>
    <arm_group_label>neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel</intervention_name>
    <description>A cycle of treatment is defined as 21 days of once daily treatment.</description>
    <arm_group_label>neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penpulimab+Anlotinib</intervention_name>
    <description>A cycle of treatment is defined as 21 days of once daily treatment.</description>
    <arm_group_label>neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early stage IIB-IIIB (N2), operable non-small cell lung cancer, confirmed in tissue.&#xD;
&#xD;
          -  Epidermal growth factor receptor/anaplastic lymphoma kinase/ROS1 gene fusions mutation&#xD;
             was negative in primary tumor or lymph node metastasis.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 with no&#xD;
             deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.&#xD;
&#xD;
          -  Lung function capacity capable of tolerating the proposed lung surgery.&#xD;
&#xD;
          -  Patients had never received surgery, chemotherapy, radiotherapy or biotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Large cell carcinoma and mixed cell lung cancer.&#xD;
&#xD;
          -  Any systemic anti-cancer treatment for NSCLC, including cytotoxic drug therapy,&#xD;
             immunotherapy, experimental treatment.&#xD;
&#xD;
          -  Prior treatment with local radiotherapy.&#xD;
&#xD;
          -  Prior treatment with any drug that targets T cell co-stimulations pathways (such as&#xD;
             checkpoint inhibitors).&#xD;
&#xD;
          -  Prior treatment with antilotinib and other antiangiogenic drugs.&#xD;
&#xD;
          -  History of hypersensitivity to any active or inactive ingredient of Penpulimab,&#xD;
             Anlotinib or chemotherapy.&#xD;
&#xD;
          -  Patients with multiple factors affecting oral medication (e.g. inability to swallow,&#xD;
             chronic diarrhea, and intestinal obstruction, etc.).&#xD;
&#xD;
          -  Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis that required steroid treatment, or any evidence of&#xD;
             clinically active interstitial lung disease.&#xD;
&#xD;
          -  Patients whose tumor has invaded important blood vessels or whose tumor is likely to&#xD;
             invade important blood vessels and cause fatal massive hemorrhage during follow-up&#xD;
             study.&#xD;
&#xD;
          -  Patients who have had arteriovenous thrombosis events within 6 months, such as&#xD;
             cerebrovascular accident (including transient ischemic attack), deep venous thrombosis&#xD;
             and pulmonary embolism.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  History of neurological or mental disorders, including epilepsy or dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Changli Wang</last_name>
    <phone>86-22-23340123 Ext. 6417</phone>
    <email>wangchangli9@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bentong Yu</last_name>
      <email>yubentong@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

